Treatment of chronic active hepatitis. An analysis of three controlled trials

Gastroenterology

Volumn 73, Issue 6, 1977, Pages 1422-1430

  Wright, E C ^a   Seeff, L B ^a   Berk, P D ^a   Jones, A ^b   Plotz, P H ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; HEPATITIS B ANTIGEN; PLACEBO; PREDNISOLONE;

CHRONIC ACTIVE HEPATITIS; CLINICAL STUDY; DIAGNOSIS; DRUG THERAPY; MAJOR CLINICAL STUDY; REVIEW; THERAPY;

EID: 0017699606     PISSN: 00165085     EISSN: None     Source Type: None    
DOI: 10.1016/s0016-5085(19)31527-6     Document Type: Article

References (40)

1. Conn H.O. Chronic hepatitis: reducing an iatrogenic enigma to a workable puzzle Gastroenterology 70 1976 1182 1184
2. Page A.R. Good R.A. Plasma-cell hepatitis with special attention to steroid therapy Am J Dis Child 99 1960 288 314
3. MacKay I.R. Wood I.J. The course and treatment of lupoid hepatitis Gastroenterology 45 1963 4 13
4. Cook G.C. Mulligan R. Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis Q J Med 40 1971 159 185
5. Murray-Lyon I.M. Stern R.B. Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis Lancet 1 1973 735 737
6. Soloway R.D. Summerskill W.H.J. Baggenstoss A.H. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatment and early prognosis Gastroenterology 63 1972 820 833
7. Mistiiis S.P. Blackburn C.R.B. Active chronic hepatitis Am J Med 48 1970 484 495
8. Wright R. McCollum R.W. Klatskin G. Australia antigen in acute and chronic liver disease Lancet 2 1969 117 121
9. Nielsen J.O. Dietrichson O. Elling P. Incidence and meaning of persistence of Australia antigen in patients with acute viral hepatitis: development of chronic hepatitis N Engl J Med 285 1971 1157 1160
10. Reynolds T.B. Peters R.L. Yamada S. Chronic active and lupoid hepatitis caused by a laxative, oxyphenisatin N Eng J Med 285 1971 813 820
11. Dudley F.J. Scheuer P.J. Sherlock S. Natural history of hepatitis- associated antigen-positive chronic liver disease Lancet 2 1972 1388 1393
12. Lipman T.O. Seeff L.B. Dobbins W.O. III Chronic active hepatitis. Prolonged survival without treatment Am J Dig Dis 22 1977 43 48
13. Plötz P.H. Asymptomatic chronic hepatitis Gastroenterology 68 1975 1629 1630
14. Summerskill W.H.J. Chronic active liver disease re-examined: prognosis hopeful Gastroenterology 66 1974 450 464
15. Henley K.S. Appleman H.D. The fading menace of chronic hepatitis Ann Intern Med 82 1975 840 841
16. Effect of prednisone on the survival of patients with cirrhosis of the liver: a report from the Copenhagen study group for liver disease Lancet 1 1969 119 121
17. Baggenstoss A.H. Soloway R.D. Summerskill W.H.J. Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution Hum Pathol 3 1972 183 198
18. Soloway R.D. Baggenstoss A.H. Schoenfield L.J. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy Am J Dig Dis 16 1971 1082 1086
19. Summerskill W.H.J. Korman M.G. Ammon H.V. Prednisone for chronic active liver disease: dose titration, standard dose and combination with azathioprine compared Gut 16 1975 876 883
20. Schalm S.W. Ammon H.V. Summerskill W.H.J. Failure of customary treatment in chronic active liver disease: causes and management Ann Clin Res 8 1976 221 227
21. s antigen Gut 17 1976 781 786
22. Vögten A.J.M. Schalm S.W. Summerskill W.H.J. Behavior of e antigen and antibody during chronic active liver disease. Relation to HB antigen-antibody system and prognosis Lancet 2 1976 126 128
23. Gifford R.H. Feinstein A.R. A critique of methodology in studies of anticoagulant therapy for acute myocardial infarction N Engl J Med 280 1969 351 357
24. Juhl E. Hilden M. Typstrup N. Effect of selection in controlled clinical trials. A supplement to the CSL prednisone trial in cirrhosis Scand J Gastroenterol 6 Suppl 9 1971 171 175
25. Chalmers T.C. Randomized controlled trials in diseases of the liver H. Popper F. Schaffner Progress in Liver Diseases V 1976 Grune & Stratton New York 450 456
26. Tygstrup N. Juhl E. Dilemmas of controlled clinical trials in hepatology F. Schaff- ner S. Sherlock C.M. Leevy The Liver and Its Diseases 1974 Intercontinental Medical Book Corp New York 64 75
27. Feinstein A.R. Clinical Biostatistics. XXII. The role of randomization in sampling, testing, allocation, and credulous idolatory (part 1) Clin Pharmacol Ther 14 1973 601 615
28. Oldham P.D. Measurement in medicine. The interpretation of numerical data 1968 English Universities Press London
29. Deming W.E. On probability as a basis for action Am Stat 29 1975 146 152
30. Meier P. Statistics and medical experimentation Biometrics 31 1975 511 529
31. Byar D.P. Simon R.M. Friedewald W.T. Randomized clinical trials, perspectives on some recent ideas N Engl J Med 295 7480 1976
32. Sacket D.L. Haynes R.B. Compliance with therapeutic regimens 1976 Johns Hopkins University Press Baltimore
33. Feinstein A.R. Clinical biostatistics. XXIII. The role of randomization in sampling, testing, allocation and credulous idolatory (part 2) Clin Pharmacol Ther 14 1973 898 915
34. Cutler S.J. Greenhouse S.W. Cornfield J. The role of hypothesis testing in clinical trials J Chronic Dis 19 1966 857 882
35. Snedecor G.W. Cochran W.G. Statistical Methods 1967 Iowa State University Press Ames, Iowa
36. Armitage P. Gehan E.A. Statistical methods for the identification and use of prognostic factors Int J Cancer 13 1974 16 36
37. Feinstein A.R. Clinical biostatistics XIV: The purposes of prognostic stratification. Clin Pharmacol Ther 13 1972 285 297
38. McPherson K. The problem of examining accumulating data more than once N Engl J Med 290 1974 501 502
39. Cornfield J. The Bayesian outlook and its applications Biometrics 25 1969 617 657
40. Cutler S.J. Ederer B.S. Maximum utilization of the life table method in analysing survival J Chronic Dis 8 1958 699 712